Two entrepreneurial engineers behind a medical footwear product for diabetics have secured £1.4m investment.
Joshua Shires and Thomas Bloomfield, the co-founders of Fyous, have created footwear using polymorphic moulding which can benefit diabetics who suffer from neuropathy which leads to a loss of sensation in their feet, and can in turn lead to foot damage, ulcers and even amputation. The Sheffield-based duo, who originally started out to make footwear for runners, secured Innovate UK's match-funded award of £700,000 having secured the same sum in private investment.
The money will be used to scale up their proprietary polymorphic moulding technology so that it can be used to make footwear components quickly. It will also go towards an 18-month clinical trial with the universities of Salford, Sheffield and Leeds as well as two NHS trusts and two National Institute for Health and Care Research organisations.
Read more: Hull bioplastics creator secures £2m series A investment to grow
Read more: Jet2 profits soar despite impact of Greek wildfires and air traffic control chaos
Fyous co-founder Thomas Bloomfield said: "Securing this funding means we’re able to continue with our development of our proprietary polymorphic moulding technology. Creating a shoe that is perfectly moulded to a patient’s feet has historically been elusive, with several alterations required which can take months, with the final shoe not always being the perfect fit.
"Our polymorphic moulding technology means that not only can we create the bespoke soles that fit each individual patient’s foot perfectly, but we can do it in a matter of hours in a standardised digital way. With the Innovate UK grant funding, we’re focusing on how we can reduce that manufacture time down to a matter of minutes with repeatability."
Joshua Shires, Fyous co-founder, said: “We started out wanting to make shoes that fit runners perfectly. Over the past few years of intensive research and design reviews, we realised that our proprietary polymorphic moulding technology, that we developed ourselves, has the potential to transform the lives of Diabetic patients, as well as people who have other medical conditions that require bespoke footwear."
Dr Dinesh Selvarajah, senior lecturer in Diabetes at the University of Sheffield and who will be overseeing the clinical trial, said: "Diabetic neuropathy is a common complication of diabetes and the leading cause of foot ulceration and amputations. Unfortunately, diabetes-related amputations have now reached an all-time high and urgent action is needed to reverse this trend.
"Innovations that reduce the risk of foot ulceration, will reduce the need for amputations. The potential for patients to receive bespoke, fitted footwear that could keep their feet healthy within a short time frame can have a considerable impact on their overall risk of foot ulceration and amputation. It’s a really exciting project which hopefully will lead to direct patient benefit and long-term cost savings for the NHS."
